il-12 transduced til
Skin Cancer
National Institutes of Health Clinical Center (CC)Cell therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
31 Active assets in the Skin Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Dana-Farber Cancer Institute | Phase 4 | BBB |
Cyclophosphamide Institute of Oncology Ljubljana | Phase 2 | BB |
Rapamycin Dana-Farber Cancer Institute | Phase 4 | BB |
Nivolumab 7 Hills Pharma, LLC | Phase 3 | BB |
Fludarabine H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
il-12 transduced til is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →